{
  "source": "PA-Med-Nec-Mycapssa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2225-5\nProgram Prior Authorization/Medical Necessity\nMedication Mycapssa™ (octreotide)\nP&T Approval Date 12/2020, 12/2021, 12/2022, 12/2023, 1/2025\nEffective Date 4/1/2025\n1. Background:\nMycapssa (octreotide) is a somatostatin analog indicated for long-term maintenance treatment\nin acromegaly patients who have responded to and tolerated treatment with octreotide or\nlanreotide. Somatostatin analogs are recommended in patients who are not candidates or who\nhave had an inadequate response to surgery.\n2. Coverage Criteria a:\nA. Acromegaly\n1. Initial Authorization\na. Mycapssa will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of acromegaly by one of the following:\ni. Serum GH level > 1 ng/mL after a 2-hour oral glucose tolerance test\n(OGTT) at time of diagnosis\nii. Elevated serum IGF-1 levels (above the age and gender adjusted normal\nrange as provided by the physician’s lab) at time of diagnosis\n-AND-\n(b) One of the following:\ni. Inadequate response to one of the following:\n• Surgical resection\n• Pituitary irradiation\n• Bromocriptine mesylate at maximally tolerated dose\n-OR-\nii. Not a candidate for any of the following:\n• Surgical resection\n• Pituitary irradiation\n• Bromocriptine mesylate at maximally tolerated dose\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(c) Patient has responded to and tolerated treatment with one of the following\nsomatostatin analogs:\ni. Sandostatin (octreotide) or Sandostatin LAR\nii. Somatuline Depot (lanreotide)\n-AND-\n(d) The provider has submitted clinical justification why the patient is unable to\nbe maintained on current octreotide or lanreotide therapy\n-OR-\n(2) Patient is currently on Mycapssa therapy for acromegaly\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Mycapssa will be approved based on the following criteria:\n(1) Documentation of positive clinical response to Mycapssa therapy\nAuthorization ",
    "zation will be issued for 12 months.\n2. Reauthorization\na. Mycapssa will be approved based on the following criteria:\n(1) Documentation of positive clinical response to Mycapssa therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Mycapssa [package insert]. Scotland, UK: MW Encap Ltd.; August 2024.\n2. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical\npractice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951.\ndoi:10.1210/jc.2014-2700\nProgram Prior Authorization/Medical Necessity - Mycapssa® (octreotide)\nChange Control\n12/2020 New program\n12/2021 Annual review with no change to clinical criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2\n12/2022 Annual review with no change to clinical criteria. Updated references.\n12/2023 Annual review with no change to clinical criteria.\n12/2024 Annual review. Updated wording of criteria without change in clinical\nintent. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}